Age at onset: An essential variable for the definition of genetic risk factors for sporadic Alzheimer's disease

Annals of the New York Academy of Sciences

Volumn 1057, Issue , 2005, Pages 260-278

  Beyer, Katrin ^a   Lao, José I ^b   Latorre, Pilar ^a   Ariza, Aurelio ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b Dr Echevarne Laboratory   (Spain)

Author keywords

Age at onset; Alzheimer's disease; Apolipoprotein E

Indexed keywords

APOLIPOPROTEIN E; CATHEPSIN D; CHOLINESTERASE; CYSTATHIONINE BETA SYNTHASE; CYSTATIN C; METHIONINE SYNTHASE;

ADULT; AGE DISTRIBUTION; AGED; ALLELE; ALZHEIMER DISEASE; CONFERENCE PAPER; CONTROLLED STUDY; DATA ANALYSIS; EARLY DIAGNOSIS; FEMALE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; ONSET AGE; POPULATION GENETICS; PROMOTER REGION; RISK FACTOR;

LONCHOCARPUS GLAUCIFOLIUS;

EID: 32244433434     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1322.021     Document Type: Conference Paper

References (90)

1. SMITH, M.A. 1998. Alzheimer disease. Int. Rev. Neurobiol. 42: 1-54.
2. ROSES, A.D. 1998. Alzheimer disease: a model of gene mutations and susceptibility polymorphisms for complex psychiatric diseases. Am. J. Med. Genet. 81: 49-57.
3. GOATE, A. et al. 1991. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349: 704-706.
4. SHERRINGTON, R. et al. 1995. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375: 754-760.
5. ROGAEV, E.I. et al. 1995. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376: 775-778.
6. ROSENBERG, R.N. 2000. The molecular and genetic basis of AD: The end of the beginning. Neurology 54: 2045-2054.
7. FARRER, L.A. et al. 1997. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. J. Am. Med. Assoc. 278: 1349-1356.
8. SAUNDERS, A.M. et al. 1993. Association of apolipoprotein E allele e4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43: 1467-1472.
9. FRISONI, G.B. et al. 1998. The prevalence of apoE-epsilon4 in Alzheimer's disease is age dependent. J. Neurol. Neurosurg. Psychiatry 65: 103-106.
10. TANG, M.X. et al. 1996. Relative risk of Alzheimer disease and age at onset distributions Caucasians and Hispanics in New York City. Am. J. Hum. Genet. 58: 574-584.
11. COMBARROS, O. et al. 2002. Candidate gene association studies in sporadic Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 14: 41-54.
12. FARRER, L.A. et al. 2000. Association between angiotensin-converting enzyme and Alzheimer disease. Arch. Neurol. 57: 210-214.
13. BLENNOW, K. et al. 2000. No association between the alpha2-macroglobulin (A2M) deletion and Alzheimer's disease, and no change in A2M mRNA, protein, or protein expression. J. Neural. Transm. 107: 1065-1079.
14. Ki, C.S. et al. 2001. Alpha-1 antichymotrypsin and alpha-2 macroglobulin gene polymorphisms are not associated with Korean late-onset Alzheimer's disease. Neurosci. Lett. 302: 69-72.
15. CRAWFORD, F.C. et al. 2000. A polymorphism in the cystatin C gene is a novel risk factor for late-onset Alzheimer's disease. Neurology 55: 763-768.
16. BEYER, K. et al. 2002. Identification of a protective allele against Alzheimer's disease in the APOE gene promoter. Neuroreport 13: 1403-1405.
17. APELT, J., K. ACH & R. SCHLIEBS. 2003. Aging-related downregulation of neprilysin, a putative beta-amyloid-degrading enzyme, in transgenic Tg2576 Alzheimer-like mouse brain is accompanied by an astroglial upregulation in the vicinity of beta-amyloid plaques. Neurosci. Lett. 339: 183-186.
18. BLALOCK, E.M. et al. 2003. Gene microarray in hippocampal aging: statistical profiling identifies novel processes correlated with cognitive impairment. J. Neurosci. 23: 3807-3819.
19. Lu, T. et al. 2004. Gene regulation and DNA damage in the ageing human brain. Nature 429: 883-891.
20. JENKINS, G. 2002. Molecular mechanisms of skin ageing. Mech. Ageing Dev. 123: 801-810.
21. ZHANG, Y. & B. HERMAN. 2002. Aging and apoptosis. Mech. Ageing Dev. 123: 245-260.
22. LONGO, V.D. & C.E. FINCH. 2002. Genetics of aging and diseases: from rare mutations and model systems to disease prevention. Arch. Neurol. 59: 1706-1708.
23. GROWDON, J. 2001. Incorporating biomoarkers into clinical drug trials in Alzheimer's disease. J. Alzheimer Dis. 3: 287-292.
24. REBECK, G.W., M. KINDY & M.J. LADU. 2002. Apolipoprotein E and Alzheimer's disease: the protective effects of ApoE2 and E3. J. Alzheimer Dis. 4: 145-154.
25. TETER, B. et al. 2002. The presence of apoE4, not the absence of apoE3, contributes to AD pathology. J. Alzheimer Dis. 4: 155-163.
26. CASELLI, R.J. et al. 1999. Preclinical memory decline in cognitively normal Apolipoprotein E epsilon 4 homozygotes. Neurology 53: 201-207.
27. POLVIKOSKI, T. et al. 1995. Apolipoprotein E, dementia, and cortical deposition of β-amyloid protein. N. Engl. J. Med. 333: 1242-1247.
28. BALES, K.R. et al. 1997. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat. Genet. 17: 263-264.
29. SHEA, T.B. & E. ROGERS. 2002. Folate quenches oxidative damage in brains of apolipo-protein E deficient mice: augmentation by vitamin E. Mol. Brain Res. 108: 1-6.
30. CHARTIER-HARLIN, M.C. et al. 1994. Apolipoprotein E, epsilon 4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer's disease: analysis of the 19q13.2 chromosomal region. Hum. Mol. Genet. 3: 569-574.
31. BULLIDO, M.J. et al. 1998. A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia. Nat. Genet. 18: 69-71.
32. ARTIGA, M.J. et al. 1998. Allelic polymorphisms in the transcriptional regulatory region of apolipoprotein E gene. FEBS Lett. 421: 105-108.
33. LAMBERT, J.C. et al. 1998. A new polymorphism in the APOE promoter associated with risk of developing Alzheimer's disease. Hum. Mol. Genet. 7: 533-540.
34. SESHADRI, S. et al. 2002. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N. Engl. J. Med. 346: 476-483.
35. SMITH, A.D. 2002. Homocysteine, B vitamins, and cognitive deficit in the elderly. Am. J. Clin. Nutr. 75: 785-786.
36. McCADDON, A. et al. 1998. Total serum homocysteine in senile dementia of Alzheimer type. Int. J. Geriatr. Psychiatry 13: 235-239.
37. CLARKE, R. et al. 1998. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer's disease. Arch. Neurol. 55: 1449-1455.
38. KRUMAN, I.I. et al. 2000. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J. Neurosci. 20: 6920-6926.
39. 12-binding domains of methionine synthase. Science 266: 1669-1674.
40. TSAI, M.Y. et al. 1999. Genetic causes of mild hyperhomocysteinemia in patients with premature occlusive coronary artery diseases. Atherosclerosis 143: 163-170.
41. WATKINS, D. et al. 2002. Hyperhomocysteinemia due to methionine synthase deficiency, cblG: structure of the MTR gene, genotype diversity, and recognition of a common mutation, P1173L. Am. J. Hum. Genet. 71: 143-153.
42. LECLERC, D. et al. 1996. Human methionine synthase: cDNA cloning and identification of mutations in patients of the cblG complementation group of folate/cobalamine disorders. Hum. Mol. Genet. 5: 1867-1874.
43. MUDD, S.H., H.L. LEVY & F. SKOVBY. 2000. Disorders of transsulfuration. In The Metabolic and Molecular Basis of Inherited Disease. C.S. Scriver, A.L. Beaudet, W.S. Sly & D. Valle, Eds.: 1279-1327. McGraw-Hill. New York.
44. KRAUS, J.P. et al. 1998. The human cystathionine beta-synthase (CBS) gene: complete sequence, alternative splicing, and polymorphisms. Genomics 52: 312-324.
45. TSAI, M.Y. et al. 1996. High prevalence of a mutation in the cystathionine beta-synthase gene. Am. J. Hum. Genet. 59: 1262-1267.
46. LIEVERS, K.J. et al. 2003. Cystathionine beta-synthase polymorphisms and hyperhomocysteinaemia: an association study. Eur. J. Hum. Genet. 11: 23-29.
47. LEVY, E. et al. 2001. Codeposition of cystatin C with amyloid-beta protein in the brain of Alzheimer's disease patients. J. Neuropathol. Exp. Neurol. 60: 94-104.
48. FINCKH, U. et al. 2000. Genetic association of a cystatin C gene polymorphism with late-onset Alzheimer's disease. Arch. Neurol. 57: 1579-1583.
49. LIGNELID, H., V.P. COLLINS & B. JACOBSSON. 1997. Cystatin C and transthyretin expression in normal and neoplastic tissues of the human brain and pituitary. Acta Neuropathol. (Berlin) 93: 494-500.
50. CATALDO, A.M. et al. 1997. Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: neuropathologic evidence for a mechanism of increased beta-amyloidogenesis. J. Neurosci. 17: 6142-6151.
51. BURSCH, W. 2001. The autophagosomal-lysosomal compartment in programmed cell death. Cell Death Diff. 8: 569-581.
52. BAHR, B.A. & J. BENDISKE. 2002. The neuropathogenic contributions of lysosomal dysfunction. J. Neurochem. 83: 481-489.
53. CATALDO, A.M. et al. 2004. Presenilin mutations in familial Alzheimer's disease and transgenic mouse models accelerate neuronal lysosomal pathology. J. Neuropathol. Exp. Neurol. 63: 821-830.
54. PAPASSOTIROPOULOS, A. et al. 2000. A genetic variation of cathepsin D is a major risk factor for Alzheimer's disease. Ann. Neurol. 47: 399-403.
55. GOMEZ-RAMOS, P., C. BOURAS & M. MORAN. 1994. Ultrastructural localization of butyrylcholinesterase on neurofibrillary degeneration sites in the brain of aged and Alzheimer's disease patients. Brain Res. 640: 17-24.
56. GUILLOZET, A.L. et al. 1997. Butyrylcholinesterase in life cycle of amyloid plaques. Ann. Neurol. 42: 909-918.
57. TASKER, A., E.K. PERRY & C.G. BALLARD. 2005. Butyrylcholinesterase: impact on symptoms and progression of cognitive impairment. Future Drugs 5: 101-106.
58. LEHMANN, D.J., C. JOHNSTON & A.D. SMITH. 1997. Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer's disease. Hum. Mol. Genet. 11: 1933-1936.
59. HOLMES, C. et al. 2005. Rate of progression of cognitive decline in Alzheimer's disease: effect of butyrylcholinesterase K gene variation. J. Neurol. Neurosurg. Psychiatry 76: 640-643.
60. McKHANN, G., G. DRACHMAN & M. FOLSTEIN. 1984. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the department of health and human services task force on Alzheimer's disease. Neurology 34: 939-944.
61. BEYER, K. et al. 2001. Alzheimer's disease and the cystatin C gene polymorphism: an association study. Neurosci. Lett. 315: 17-20.
62. MATSUO, K. et al. 2001. Association between polymorphisms of folate- and methionine-metabolizing enzymes and susceptibility to malignant lymphoma. Blood 97: 3205-3209.
63. BEYER, K. et al. 2004. Cystathionine beta synthase as risk factor for Alzheimer's disease. Curr. Alzheimer Res. 1: 127-133.
64. BALBÍN, M., A. GRUBB & M. ABRAHAMSON. 1993. An Ala/Thr variation in the coding region of the human cystatin C gene (CST3) detected as a SstII polymorphism. Hum. Genet. 92: 206-207.
65. MdILROY, S.P. et al. 1999. Cathepsin D gene exon 2 polymorphism and sporadic Alzheimer's disease. Neurosci. Lett. 273: 140-141.
66. WIEBUSCH, H. et al. 1999. Further evidence for a synergistic association between APOEε4 and BCHE-K in confirmed Alzheimer's disease. Hum. Genet. 104: 158-163.
67. BEYER, K. et al. 2002. The Th1/E47cs-G APOE promoter allele is a risk factor for Alzheimer's disease of very late onset. Neurosci. Lett. 326: 187-190.
68. LIEVERS, K.J. et al. 2001. A 31 bp VNTR in the cystathionine beta-synthase (CBS) gene is associated with reduced CBS activity and elevated post-load homocysteine levels. Eur. J. Hum. Genet. 9: 583-589.
69. FRANCO, R. et al. 1998. The frequency of 844ins68 mutation in the cystathionine beta-synthase gene is not increased in patients with venous thrombosis. Haematologica 83: 1006-1008.
70. GIUSTI, B. et al. 1997. Different distribution of the double mutant "T833C/68 bp insertion" in cystathionine beta-synthase gene in Northern and Southern Italian populations. Thromb. Haemost. 78: 1293.
71. BEYER, K. et al. 2003. Methionine synthase polymorphism is a risk factor for Alzheimer's disease. Neuroreport 14: 1391-1394.
72. McCARRON, M.O. et al. 1999. The apolipoprotein epsilon 2 allele and the pathological features in cerebral amyloid angiopathy-related hemorrhage. J. Neuropathol. Exp. Neurol. 58: 711-718.
73. TOUITOU, I. et al. 1994. Missense polymorphism (C/T244) in the human cathepsin D profragment determined by polymerase chain reaction single strand conformation polymorphism analysis and possible consequences in cancer cells. Eur. J. Cancer 30: 390-394.
74. SOININEN, H. et al. 1995. A severe loss of choline acetyltransferase in the frontal cortex of Alzheimer patients carrying apolipoprotein ε4 allele. Neurosci. Lett. 187: 79-82.
75. LAMBERT, J.C. et al. 1998. Pronounced impact of Th1/E47cs mutation compared with -491 AT mutation on neural APOE gene expression and risk of developing Alzheimer's disease. Hum. Mol. Genet. 7: 1511-1516.
76. HALIMI, G. et al. 2000. Association of APOE promoter but not A2M polymorphisms with risk of developing Alzheimer's disease. Neuroreport 11: 3599-3601.
77. REBECK, G.W. et al. 1999. Lack of independent associations of apolipoprotein E promoter and intron 1 polymorphisms with Alzheimer's disease. Neurosci. Lett. 272: 155-158.
78. TOJI, H. et al. 1999. Apolipoprotein E promoter polymorphism and sporadic Alzheimer's disease in a Japanese population. Neurosci. Lett. 259: 56-58.
79. McILROY, S.P. et al. 2002. Moderately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype, and risk for stroke, vascular dementia, and Alzheimer's disease in Northern Ireland. Stroke 33: 2351-2356.
80. BRUNELLI, T. et al. 2001. The C677T methylenetetrahydrofolate reductase mutation is not associated with Alzheimer's disease. Neurosci. Lett. 315: 103-105.
81. SERIPA, D. et al. 2003. Methylenetetrahydrofolate reductase and angiotensin converting enzyme gene polymorphisms in two genetically and diagnostically distinct cohort of Alzheimer patients. Neurobiol. Aging 24: 933-939.
82. POSTIGLIONE, A. et al. 2001. Plasma folate, viiamin B(12), and total homocysteine and homozygosity for the C677T mutation of the 5,10-methylene tetrahydrofolate reductase gene in patients with Alzheimer's dementia. A case-control study. Gerontology 47: 324-329.
83. NISHIYAMA, M. et al. 2000. Apolipoprotein E, methylenetetrahydrofolate reductase (MTHFR) mutation and the risk of senile dementia: an epidemiological study using the polymerase chain reaction (PCR) method. J. Epidemiol. 10: 163-172.
84. REGLAND, B. et al. 1999. The role of the polymorphic genes apolipoprotein E and methylene-tetrahydrofolate reductase in the development of dementia of the Alzheimer type. Dement. Geriatr. Cogn. Disord. 10: 245-251.
85. MARUYAMA, H. et al. 2001. Lack of an association between cystatin C gene polymorphisms in Japanese patients with Alzheimer's disease. Neurology 57: 337-339.
86. ROKS, G. et al. 2001. The cystatin C polymorphism is not associated with early onset Alzheimer's disease. Neurology 57: 366-367.
87. NTAIS, C., A. POLYCARPOU & J.P.A. IOANNIDIS. 2004. Meta-analysis of the association of the cathepsin d ala224val gene polymorphism with the risk of Alzheimer's disease: a huge gene-disease association review. Am. J. Epidemiol. 159: 527-536.
88. HILTUNEN, M. et al. 1998. Butyrylcholinesterase K variant and apolipoprotein E4 genes do not act in synergy in Finnish late-onset Alzheimer's disease patients. Neurosci. Lett. 250: 69-71.
89. GRUBBER, J.M. et al. 1999. Analysis of associaton between Alzheimer disease and the variant of butyrylcholinesterase (BCHE-K). Neurosci. Lett. 269: 115-119.
90. CRAWFORD, F. et al. 1998. The butyrylcholinesterase gene is neither independently nor synergistically associated with late-onset AD in clinic and community-based populations. Neurosci. Lett. 249: 115-118.